Long COVID

WikiDoc Resources for Long COVID
Articles
Most recent articles on Long COVID Most cited articles on Long COVID Review articles on Long COVID Articles on Long COVID in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Long COVID Images of Long COVID Photos of Long COVID Podcasts & MP3s on Long COVID Videos on Long COVID
Evidence Based Medicine
Cochrane Collaboration on Long COVID Bandolier on Long COVID TRIP on Long COVID
Clinical Trials
Ongoing Trials on Long COVID at Clinical Trials.gov Trial results on Long COVID Clinical Trials on Long COVID at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Long COVID NICE Guidance on Long COVID NHS PRODIGY Guidance FDA on Long COVID CDC on Long COVID
Books
Books on Long COVID
News
Long COVID in the news Be alerted to news on Long COVID News trends on Long COVID
Commentary
Blogs on Long COVID
Definitions
Definitions of Long COVID
Patient Resources / Community
Patient resources on Long COVID Discussion groups on Long COVID Patient Handouts on Long COVID Directions to Hospitals Treating Long COVID Risk calculators and risk factors for Long COVID
Healthcare Provider Resources
Symptoms of Long COVID Causes & Risk Factors for Long COVID Diagnostic studies for Long COVID Treatment of Long COVID
Continuing Medical Education (CME)
CME Programs on Long COVID
International
Long COVID en Espanol Long COVID en Francais
Business
Long COVID in the Marketplace Patents on Long COVID
Experimental / Informatics
List of terms related to Long COVID

For COVID-19 main page, click here

For COVID-19 frequently asked inpatient questions, click here

For COVID-19 frequently asked outpatient questions, click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];

Synonyms and keywords: Long COVID Syndrome, long COVID, long-haul COVID, post-COVID-19 condition, post-COVID-19 syndrome, post-acute sequelae of COVID-19 (PASC), chronic COVID syndrome (CCS).

Overview

• Shortly after the COVID-19 pandemic onset, emerging studies showed that a considerable proportion of patients with COVID-19 might exhibit sustained postinfection sequelae.

Historical Perspective

• The term ‘Long COVID’ was first used as a Twitter hashtag by a patient who was not recovering from COVID-19. This patient-made term soon became a widely accepted concept by both the public and medical professionals.
• Currently, this condition is known by a variety of names, including long COVID, long-haul COVID, post-COVID-19 condition, post-COVID-19 syndrome, post-acute sequelae of COVID-19 (PASC), or chronic COVID syndrome (CCS).
• This condition is listed in the ICD-10 classification as post-COVID-19 condition since September 2020.
• On October 6, 2021, World Health Organization (WHO) released a clinical case definition of the post-COVID-19 condition through a robust, protocol-based methodology (Delphi consensus), which engaged a diverse group of representative patients, patient-researchers, external experts, WHO staff, and other stakeholders from multiple geographies. It was acknowledged that this definition may change with emerging new evidence and continuously evolving our understanding of the consequences of COVID-19.
• According to WHO clinical case definition, the post-COVID-19 condition is defined as:
  • Post COVID-19 condition occurs in individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis. Common symptoms include fatigue, shortness of breath, cognitive dysfunction and generally have an impact on everyday functioning. Symptoms may be new-onset following initial recovery from an acute COVID-19 episode or persist from the initial illness. Symptoms may also fluctuate or relapse over time.
  • A separate definition may be applicable for children.
  • Notes: There is no minimum number of symptoms required for the diagnosis; though symptoms involving different organs systems and clusters have been described.

• Other published/available definitions of the post-COVID-19 condition include:
  • CDC: Long COVID: "While most persons with COVID-19 recover and return to normal health, some patients can have symptoms that can last for weeks or even months after recovery from acute illness. Even people who are not hospitalized and who have a mild illness can experience persistent or late symptoms."
  • Nature: Post-acute COVID-19 as persistent symptoms and/or delayed or long-term complications of SARS-CoV-2 infection beyond 4 weeks from the onset of symptoms.
  • Lancet: Multiorgan symptoms after COVID-19 are being reported by increasing numbers of patients. They range from cough and shortness of breath to fatigue, [[[headache]], palpitations, chest pain, joint pain, physical limitations, depression, and insomnia, and affect people of varying ages. At the Lancet–Chinese Academy of Medical Sciences conference on 23 November 2020, Bin Cao presented data (in press at the Lancet) on the long-term consequences of COVID-19 for patients in Wuhan and warned that dysfunctions and complications could persist in some discharged patients for at least 6 months. So-called long COVID is a burgeoning health concern and action is needed now to address it.
  • NICE: Signs and symptoms that develop during or after an infection consistent with COVID-19, continue for more than 12 weeks and are not explained by an alternative diagnosis.
  • Scientific American:Individuals whose symptoms persist or develop outside the initial viral infection, but the duration and pathogenesis are unknown.
  • Royal Society: The onset of persistent or recurrent episodes of one or more of the following symptoms, within x* weeks of infection with SARS-CoV-2 and continuing for y* weeks or more: severe fatigue, reduced exercise capacity, chest pain or heaviness, fever, [[palpitations[[, cognitive impairment, anosmia or ageusia, vertigo and tinnitus, headache, peripheral neuropathy, metallic or bitter taste, skin rash, joint pain or swelling.
    • Maximum period between acquisition of the infection (if known) and the onset of symptoms, and the minimum duration of symptoms, should be specified in the definition.
  • Haute Autorité de santé, France: Three criteria: Having presented with symptomatic form of COVID-19; presenting with one or more initial symptoms 4 weeks after the start of the disease, and none of these symptoms can be explained by another diagnosis.

Classification

There is no established system for the classification of long COVID.

Pathophysiology

The exact pathogenesis of long COVID is not fully understood.

Epidemiology and Demographics

• The reported incidence/prevalence of long COVID-19 varies in different studies mainly due to the absence of single terminology and definition.
• One study found that up to 70% of individuals at low risk of mortality from COVID-19 experience impairment in one or more organs (including heart, lungs, kidneys, liver, pancreas, or spleen) 4 months after acute COVID-19 episode.
• A meta-analysis, including 47,910 patients (age 17-87 years), estimated that 80% of the patients with SARS-CoV-2 infections developed one or more long-term (ranging from 14 to 110 days) symptoms.
• Women seem to be more commonly affected by long COVID than men.

Risk Factors

• There are no established risk factors for long COVID.
• However, according to several studies, the most common risk factors for the development of long COVID may include:
  • Older age
  • Female gender
  • Preexisting comorbidities, such as obesity, asthma
  • More severity of the acute COVID-19 episode, including a prolonged hospitalization or ICU stay
    • However, emerging data suggest that even patients with a less severe initial episode of COVID-19, who had not required hospitalization, may also experience persistent symptoms of post-COVID-19 condition
  • Medical complications during acute COVID-19 episode, such as secondary bacterial pneumonia, venous thromboembolism
  • Presence of a higher number of symptoms in the acute COVID-19 episode (i.e. an extended spectrum of symptoms)

Screening

There is insufficient evidence to recommend routine screening for long COVID.

Natural History, Complications, and Prognosis

• The natural history, clinical course, long-term complications, and prognosis of long COVID-19 are still not completely understood.
• Manifestations of the post-COVID-19 condition vary considerably in terms of organ involvement and severity of symptoms; however, they generally impact the everyday functioning of affected patients.
• Symptoms might newly develop following initial recovery from an acute COVID-19 illness or occur as a persist from the initial episode.
• Symptoms might also fluctuate or relapse over time.

Diagnosis

Diagnostic Study of Choice

• According to a clinical case definition by WHO, the post-COVID-19 condition is defined as follow:
  • The post-COVID-19 condition occurs in individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset, with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis.

History and Symptoms

Long COVID can involve almost every organ. The most common symptoms of long COVID include:

• Physical symptoms:
  • Fatigue
  • Dyspnea
  • Cough
  • Chest discomfort
  • Anosmia

• Neurocognitive symptoms:
  • Memory impairment and Cognitive dysfunction: described by patients as “brain fog”
  • Headache

• Psychologic symptoms:
  • Anxiety
  • Depression
  • Post-traumatic stress disorder (PTSD)

• Other less common symptoms include:
  • Sweating
  • Myalgias
  • Diarrhea
  • Hair Loss (Alopecia)
  • Joint Pain
  • Sicca Syndrome
  • Rhinitis
  • Dysgeusia
  • Poor Appetite
  • Dizziness
  • Vertigo
  • Insomnia

Physical Examination

• In patients with cardiopulmonary symptoms, a throughout chest examination may provide a clue to the underlying condition:
  • On pulmonary examination:
    • Coarse crackles: a sign of fibrosis
    • Dullness on percussion: a sign of pleural effusion or consolidation
    • Egophony: A sign of consolidation
    • Fine basilar crackles: A sign of pulmonary edema
  • On cardiac examination, the following findings may provide a clue to the underlying cardiac complication:
    • Jugular venous distension
    • Peripheral edema
  • *Orthostasis
    • Murmurs
    • Pericardial rub
    • Third or fourth heart sounds

Laboratory Findings

There are no diagnostic laboratory findings associated with long COVID. Symptoms do not correlate with the serology of SARS-CoV-2.

Electrocardiography

In patients with cardiopulmonary symptoms, an ECG may be needed.

X-ray

A chest x-ray may be helpful in the diagnosis of pulmonary complications of COVID such as lung damage (ie, ground glass opacities, consolidation, interlobular septal thickening), pleural effusion.

Echocardiography or Ultrasound

In selected patients with cardiopulmonary symptoms, echocardiography may be necessary.

CT scan

In patients with cardiopulmonary symptoms, a chest CT scan may be needed.

MRI

There are no MRI findings associated with long COVID. However, a cardiac MRI may be helpful in the diagnosis of myocarditis in COVID-19 patients.

Other Imaging Findings

There are no other imaging findings associated with long COVID.

Other Diagnostic Studies

In selected patients with cardiopulmonary symptoms, Holter monitoring, cardiopulmonary exercise testing (CPET), and pulmonary function tests may be necessary.

Treatment

Due to the diversity of symptoms and their severity, the mainstay of long COVID treatment is multidisciplinary and supportive. The management should focus on supporting self-management and individualized rehabilitation.

Medical Therapy

• Dyspnea
  • Dyspnea in long COVID patients should be treated similar to non-COVID-19 patients. General measures in the management of dyspnea in long COVID patients may include:
    • Oxygen therapy
    • Breathing exercises
      • Pursed lip breathing exercises
      • Deep breathing exercises
    • Pulmonary rehabilitation
  • In the presence of any identified underlying cardiac or pulmonary disease, referral to a cardiologist or pulmonologist and appropriate pharmacotherapy may be required.

• Cough
  • Cough should be managed in a similar to cough in patients with post-viral cough syndrome.
  • Attention should be paid to diagnose and treat other exacerbating or contributing factors such as gastrointestinal reflux disease and asthma.
  • Over-the-counter cough suppressants, including benzonatate, guaifenesin, and dextromethorphan are the mainstay of treatment.

• Cardiac injury
  • Long COVID patients with evidence of cardiac injury should be referred to cardiology services.

• Orthostasis
  • Orthostasis and dysautonomia, such as unexplained sinus tachycardia, dizziness on standing, is initially managed conservatively with compression stockings, abdominal binder, increased intake of fluid and salts, physical therapy/rehabilitation, and behavioral modifications.
  • In patients with postural orthostatic tachycardia syndrome (PoTS) and inadequate response to non-pharmacological therapy, beta-blockers, ivabradine, or fludrocortisone (with blood pressure and response monitoring) might be considered.

• Olfactory/gustatory symptoms
  • In most patients with a loss or decrease in sense of smell or taste, symptoms improve slowly over several weeks and do not require medical intervention. Patients may need education on food and home safety.
  • In patients with persistent symptoms, olfactory training may be appropriate. If conservative management fails, referral to an otolaryngologist and specialized taste and smell clinic may also be considered.

• Fatigue
  • A Consensus Guidance Statement provides practical guidance to clinicians in the treatment of fatigue in postacute sequelae of SARS‐CoV‐2 infection (PASC) patients.
    • Conservative management
      • 1) Initiation of an individualized and structured, titrated return to activity program.
        • The goal of such a rehabilitation program should be restoring patients to their previous levels of activity and improve quality of life
        • The titration approach ensures that patients are engaged in activities at a submaximal level to avoid exacerbation of fatigue.
        • Level of activity should be adjusted according to change in fatigue-related symptoms that develop during or after activity.
      • 2) Educating patients on energy conservation strategies
      • 3) Encouraging a healthy diet and adequate hydration
      • 4) Treatment of any underlying medical conditions such as pain, insomnia/sleep disorders (including poor sleep hygiene), and mood problems that may be contributing and/or aggravating fatigue.
    • Pharmacologic therapy and supplements
      • A number of herbal remedies/supplements and pharmacologic agents have been used in the treatment of chronic fatigue in other causes of chronic illness (eg, multiple sclerosis, fibromyalgia, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), cancer, brain injury, and Parkinson's disease).
      • These include:
        • Branched‐chain amino acids
        • Omega 3 fatty acids
        • Vitamin B12
        • Vitamin C
        • Vitamin D
        • Magnesium
        • L‐carnitine
        • Coenzyme Q10
        • Ginseng
        • Echinacea
        • Amantadine
        • Modafinil
        • Methylphenidate
        • Antivirals/antibiotics/antiparasitics
        • Antidepressants
        • Cytokine inhibitors
        • Galantamine
        • Glucocorticoids
        • Immunoglobulins
        • Rituximab
      • However, it should be noted that due to limited scientific evidence, currently there is no general consensus on routine administration of these supplements/medications. Thus, they may be considered on a case‐by‐case basis.
      • Other therapeutic interventions such as acupuncture have been suggested in the treatment of fatigue.

• Weight loss
  • In patients with long COVID, weight loss is multifactorial and may occur due to a combination of malnutrition, loss of appetite, catabolic state, swallowing difficulty, and alterations in taste and smell.
  • Patients should be encouraged to eat small, frequent meals with protein and calorie supplementation. Nutrition consultation and referral to a dietician may be required in selected patients with severe weight loss.

• Psychological and emotional issues
  • In patients experiencing emotional distress, mood disturbances, anxiety, or symptoms of post-traumatic stress disorder, mental health assessment and possible referral to a psychiatrist may be required.

• Alopecia
  • There is no specific therapy for alopecia in COVID-19 patients, and it should be managed similarly to non-COVID-19 patients.
  • In patients with concomitant malnutrition, nutritional deficiencies should be corrected.

• Insomnia
  • All patients with insomnia should be educated on sleep hygiene guidelines, stimulus control instructions, and relaxation techniques. Short-term pharmacologic treatment with benzodiazepines or non-benzodiazepine hypnotics may be needed in selected patients.

Primary Prevention

The most effective measure to prevent the post-COVID-19 condition is to prevent COVID-19. These primary prevention strategies include:

• Vaccination
• Masking
• Social distancing
• Hand hygiene

Secondary Prevention

There are no established measures for the secondary prevention of [long COVID].